

Supplementary table S1. The “Detailed” method. Change from baseline in Nvoxel, IRE and ME

	CZP		PBO+CZP	
	n	Median (Range)	n	Median (Range)
Nvoxel				
PIP2-4				
Week 1	6	0 (-144–511)	3	-35 (-393– -32)
Week 2	7	12 (-170–145)	5	-56 (-609–262)
Week 4	4	-75 (-446–0)	5	-80 (-617–113)
Week 8	10	10 (-370–396)	7	-69 (-884–15)
Week 16	8	-12 (-765–103)	5	-32 (-760–26)
MCP2-4				
Week 1	4	-503 (-1470–77)	1	14*
Week 2	5	0 (-1079–596)	2	62 (-63–186)
Week 4	5	0 (-1045–87)	1	0*
Week 8	4	53 (0–890)	2	90 (-20–199)
Week 16	5	-473 (-1682–66)	1	0*
Initial Rate of Enhancement				
PIP2-4				
Week 1	3	-0.00 (-0.01–0.00)	2	0.00 (-0.01–0.00)
Week 2	5	0.00 (-0.5–0.2)	5	0.00 (-0.03–0.00)
Week 4	3	0.00 (0.00–0.01)	5	0.00 (-0.04–0.11)
Week 8	5	0.00 (-0.53–0.02)	5	0.01 (0.00–0.21)
Week 16	2	0.02 (0.00–0.04)	4	0.00 (0.00–0.00)
MCP2-4				
Week 1	3	-0.00 (-0.01–0.01)	0	-
Week 2	2	-0.00 (0.00–0.00)	2	0.01 (0.00–0.01)
Week 4	4	0.00 (-0.04–0.00)	0	-
Week 8	2	-0.02 (-0.05–0.00)	2	0.27 (0.00–0.55)
Week 16	5	0.00 (-0.04–0.02)	0	–
Maximum Enhancement				
PIP2-4				
Week 1	3	-0.30 (-0.51–0.06)	2	-0.16 (-1.00–0.13)
Week 2	5	0.02 (-0.31–0.18)	5	-0.17 (-0.73–0.51)
Week 4	3	0.03 (-0.54–0.05)	5	-0.26 (-0.35–0.08)
Week 8	5	-0.01 (-0.60–0.36)	5	-0.02 (-0.49–0.60)
Week 16	2	-0.12 (-0.61–0.37)	4	-0.19 (-0.60–0.02)
MCP2-4				
Week 1	3	-0.34 (-0.40–0.03)	0	-
Week 2	2	-0.01 (-0.35–0.34)	2	0.37 (0.12–0.63)
Week 4	4	0.13 (0.11–0.53)	0	-
Week 8	2	-0.36 (-0.16–0.08)	2	0.06 (-0.26–0.37)
Week 16	5	-0.23 (-0.49–0.19)	0	-

Median changes (Range) from baseline.

* Exact Value. Nvoxel: number of enhancing voxels; IRE: Initial Rate of Enhancement; ME:

Maximum Enhancement; n: Number of patients that were included and fulfilled the predefined

imaging criteria; CZP: Certolizumab Pegol; PBO: Placebo; CI: confidence interval; PIP: proximal

interphalangeal joint; MCP: metacarpophalangeal joint.